ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.695A>G (p.Tyr232Cys) (rs372188754)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000129831 SCV000184647 likely benign Hereditary cancer-predisposing syndrome 2018-09-28 criteria provided, single submitter clinical testing In silico models in agreement (benign);Other data supporting benign classification
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000656999 SCV000232905 uncertain significance not provided 2015-04-16 criteria provided, single submitter clinical testing
Invitae RCV000200246 SCV000254202 likely benign Hereditary breast and ovarian cancer syndrome 2019-11-25 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000239053 SCV000296750 uncertain significance Breast-ovarian cancer, familial 2 2016-04-13 criteria provided, single submitter clinical testing
GeneDx RCV000656999 SCV000565866 uncertain significance not provided 2017-06-21 criteria provided, single submitter clinical testing This variant is denoted BRCA2 c.695A>G at the cDNA level, p.Tyr232Cys (Y232C) at the protein level, and results in the change of a Tyrosine to a Cysteine (TAT>TGT). Using alternate nomenclature, this variant would be defined as BRCA2 923A>G. This variant has not, to our knowledge, been published in the literature as pathogenic or benign. BRCA2 Tyr232Cys was not observed at a significant allele frequency in large population cohorts (NHLBI Exome Sequencing Project, The 1000 Genomes Consortium 2015, Lek 2016). Since Tyrosine and Cysteine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. BRCA2 Tyr232Cys occurs at a position that is not conserved and is not located in a known functional domain. In silico analyses predict that this variant is unlikely to alter protein structure or function. Based on currently available evidence, it is unclear whether BRCA2 Tyr232Cys is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000656999 SCV000889117 uncertain significance not provided 2019-03-22 criteria provided, single submitter clinical testing
Color RCV000129831 SCV000911097 likely benign Hereditary cancer-predisposing syndrome 2016-06-14 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.